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BACKGROUND The Impella (Abiomed, Inc.) is a percutaneous left
ventricular assist device. It can be used in patients presenting with
acute myocardial infarction (AMI) complicated by cardiogenic shock
(CS) or in the elective setting for patients undergoing high-risk
percutaneous coronary intervention (PCI). Recently, the more
powerful Impella 4.0 (generating output up to 4L/min) was intro-
duced. In this retrospective study, we investigated 30-day outcome in
patients supported by Impella 2.5 or 4.0 in the acute setting of
cardiogenic shock.
METHODS From January 2009 till January 2015, 50 patients were
supported with the Impella-device in the Catharina Hospital Eind-
hoven, the Netherlands (a high-volume PCI centre). The Impella 2.5
was implanted from 2009 till 2013 and from 2013 the Impella 4.0 was
implanted exclusively. Study end point was 30-day survival.
RESULTS Patient characteristics were similar between the patient
groups treated by Impella 4.0 and Impella 2.5, respectively (table). Of
all 50 patients, 24 presented with AMI complicated by CS, 6 presented
with CS from other cause and 20 underwent high-risk elective PCI. In
the AMI plus CS-group, 13 patients were treated with Impella 4.0 and
11 patients were treated with Impella 2.5. All these patients were
treated by PCI and after 30 days, survival in the AMI plus CS Impella
4.0-group was signiﬁcantly higher compared to the AMI plus CS
Impella 2.5-group (46% versus 9%, P¼0.02) (ﬁgure). In patients
undergoing high-risk elective PCI, there was no difference in 30-day
survival between Impella 4.0 and Impella 2.5 (63% versus 61%,
P¼0.87).
Table. Baseline characteristicsImpella 4.0 acute + PCI (13) Impella 2.5 acute + PCI (11)Age (yrs) 5712 669
Male 9 (69%) 7 (64%)Diabetes 3 (23%) 3 (27%)Hypertension 6 (46%) 5 (45%)Hypercholesterolemia 2 (15%) 3 (27%)BMI (kg/cm2) 254 273
Previous MI 2 (15%) 2 (18%)Previous PCI 0 (0%) 1 (9%)Previous CABG 0 (0%) 0 (0%)Resuscitation 6 (46%) 7 (64%)Cardiogenic shock 13 (100%) 11 (100%)PCI 13 (100%) 11 (100%)LVEF < 30% 10 (77%) 9 (82%)MI ¼Myocardial infarction; PCI ¼ Percutaneous coronary intervention; CABG ¼ Coronary artery bypass graft;
LVEF ¼ Left ventricular ejection fractionCONCLUSIONS In this retrospective analysis, Impella 4.0 improved
survival signiﬁcantly in patients with AMI complicated by CS under-
going PCI compared to Impella 2.5. These novel ﬁndings support the
concept of the Impella-device. Randomized trials with the Impella 4.0
are warranted.
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BACKGROUND The Impella Circulatory Support System has been
developed to unload the left ventricle in patients with severely
reduced systolic function and to maintain basic circulation patients
with cardiogenic shock due to left-ventricular failure. We enrolled all
patients undergoing implantation of an Impella-pump in our depart-
ment into a registry to further analyze patient characteristics and
predictors of outcome.
METHODS Since July 2011 all patients, who received an Impella
microaxial pump were enrolled in our registry. Data on baseline
characteristics and in-hospital treatment including cardiovascular risk
factors, details on coronary angiography, hemodynamic parameters,
and laboratory parameters were documented in detail. Furthermore,
data on the outcome of those patients including follow-up until 12
months after implantation were recorded. In total, until June 2015, 175
patients underwent implantation of an Impella pump at our center.
Complete data including follow-up until 12 months are available in
100 patients.
RESULTS Cardiogenic shock was the indication for implantation in
85% of the cases, in the other patients the purpose for the implanta-
tion were high-risk percutaneous coronary interventions. In shock
patients mean age was 62 years (19-83 years). 74% of the patients were
male. Coronary heart disease was excluded by coronary angiography
in 21%. Median device time was 5 days (interquartile range (IQR) 1-7
days). In-hospital mortality was 8.3% in patients with isolated left-
ventricular dysfunction. Relevant contributors to worsened prognosis
were concomitant right-ventricular failure, necessity of additive
ECMO, new-onset dialysis, and pre-procedural cardiopulmonary
resuscitation. Higher body mass index (28.3 vs 25.9; p<0.01), right
heart failure (42% vs. 11%, p<0.05) and persistently elevated central
venous pressure after 6 hours (15 mmHg vs. 11 mmHg, p<0.05) were
more common in non-survivors. Neurological outcome was CPC class
1&2 in 91% of survivors. Average lactate levels were 6.7 mmol/L
(survivors) and 7.6 mmol/L (non-survivors; p¼0.652) during admis-
sion, 3.2 mmol/L (survivors) and 5.9 mmol/L (non-survivors; p¼0.028)
1h after Impella implantation, and 2.2 mmol/L (survivors) and 5.9
mmol/L (non-survivors; p¼0.008) 4h after Impella implantation.
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frequently in cardiogenic shock patients. Our preliminary data
emphasize the impact on early improvement in hemodynamic pa-
rameters and rapid lowering of lactate levels. Consequent and early
use of a microaxial pump in left-ventricular failure signiﬁcantly con-
tributes to improved survival.
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BACKGROUND High-risk surgical patients for transcatheter aortic
valve replacement (TAVR) represent an emerging population, which
may beneﬁt from short-term use of mechanical support devices
(MSD). We assessed outcomes of TAVRs performed with elective or
emergent “bail-out” placement of MSD.
METHODS All patients undergoing TAVR at a high volume academic
center who required MSD during index procedure between the years
2008-2015 were included.
RESULTS MSD were used in 12.4% (59/475) of all TAVRs (n¼56
Edwards Sapien) of which 70% (n¼41) were used as part of a planned
strategy, and 30% (n¼18) were used in “bail-out” situations. 25% (15/
59) required cardiopulmonary resuscitation and 14% (8/59) required a
second device (Impella or cardiopulmonary bypass, CPB after intra-
aortic balloon pump, IABP). Mean STS was 10 2.66%, 86% had
multivessel coronary artery disease and 69% underwent transapical
TAVR. IABP (81%) was the most commonly used device followed by
CPB and Impella. MSD were placed electively in patients with severe
left ventricular dysfunction undergoing concomitant coronary inter-
vention or balloon valvuloplasty whereas “bail-out” indications were
procedural complications including cardiac arrest (VT/VF) (n¼5), re-
fractory hypotension (n¼5), cardiac tamponade (n¼2), severe aortic
insufﬁciency (n¼2), stone heart or LV failure (n¼2), valve emboliza-
tion (n¼1), and left main obstruction + PCI (n¼1). Mean duration of
support was 1-day and device related complications were low (3%). In-
hospital mortality in this extremely high risk population was 17% (8%
for elective cases and 44% for emergent cases) compared to 5% in
patients without MSD use (control group). Cardiogenic shock (50%)
was the most common cause of in-hospital death followed by respi-
ratory and multi-organ failure. The cumulative all-cause mortality at
one-year follow-up was 71% (90% for elective and 50% for emergent
cases) (Figure 1).CONCLUSIONS Use of MSD in TAVR is associated with a signiﬁcantly
high mortality rates. The dismal long-term survival especially in the
elective MSD group raises concerns about the use of MSD and perhaps
futility of TAVR in this high-risk patient population.
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BACKGROUND The 6-Fr Glidesheath Slender that has a thinner wall
structure and the same outer diameter compared to the conventional
5-Fr introducer has been introduced for trans-radial coronary inter-
vention. The aim of this study was to evaluate the feasibility and
safety of the 6-Fr Glidesheath Slender for use with the 6-Fr intra-
aortic balloon pump (IABP) catheter.
METHODS Between May 2014 and March 2015, 24 patients with acute
coronary syndrome underwent percutaneous coronary intervention
using a 6-Fr IABP catheter with a balloon volume of 30 ml through a 6-
Fr Glidesheath Slender for support. The adverse events, including
access site complications, kinking of the sheath during the procedure,
and any evidence of balloon pump failure, were retrospectively
investigated.
RESULTS Insertion of the IABP catheter through either the femoral or
brachial artery was successful in all patients. The mean support time
was 32.4  22.0 h. No major hemorrhagic event or severe limb
ischemia was observed. Kinking of the shaft occurred during insertion
in one patient; however, the subsequent balloon pumping was well
maintained and did not require exchange of the sheath or IABP
catheter. No kind of IABP failure was observed.Virtual 5-Fr IABPBaseline Patient Characteristics and ResultsAge (years) 68.9  9.8
Male gender (%) 16 (66.7)Height (cm) 159.5  10.5
Body weight (kg) 59.0  10.7
Body surface area (m2) 1.60  0.19
IABP approach site - femoral (%) 24 (95.8)IABP approach site - brachial (%) 3 (12.5)Support time of IABP (hr) 32.4  22.0
Kinking of sheath introducer (%) 1 (4.2)Access site complication (%) 0 (0)CONCLUSIONS Although this sheath was originally designed to allow
radial access, our results suggest that the use of the Glidesheath
Slender is feasible for insertion of the 6-Fr IABP catheter through the
brachial and femoral arteries, and may reduce vascular complications
in patients who undergo percutaneous coronary intervention.
